drugs

Oppenheimer’s best SMID-cap ideas: AI, health, obesity drugs, and more (NYSEARCA:IWO)

ryasick/E+ via Getty Images SMID-cap growth stocks (NYSEARCA:IWO) strike an attractive balance between secular growth leadership and intermediate-term rotation potential, said Oppenheimer analysts in a Technical Analysis note. Analysts updated their best SMID-cap ideas for the year, providing exposure to high-growth themes, such as artificial intelligence, health and wellness, obesityContinue Reading

Mizuho starts Neumora at outperform, bullish on lead drug’s prospects (NASDAQ:NMRA)

In: Finance

peterschreiber.media Mizuho started coverage of Neumora Therapeutics (NASDAQ:NMRA) with an outperform rating, stating it sees 50%+ upside to the stock if the company reports positive Phase 3 data for its lead drug navacaprant in the treatment of major depressive disorder. The investment bank noted the Phase 3 data is expectedContinue Reading

Study links GLP-1 drugs, metformin to lower risk of certain cancers (NYSE:NVO)

In: Finance

A new study has linked the use of GLP-1 drugs and metformin to a lower risk of developing certain obesity-related cancers in patients with Type 2 diabetes. The study, which was published Friday on the JAMA Network Open website, showed that patients taking GLP-1 drugs or metformin showed a significantlyContinue Reading

J&J Carvykti beat standard drugs in blood cancer (NYSE:JNJ)

In: Finance

Hailshadow Johnson & Johnson (NYSE:JNJ) announced Tuesday that its FDA-approved cell therapy Carvykti, developed with Legend Biotech (LEGN), outperformed standard of care in a Phase 3 trial for patients with a type of blood cancer called multiple myeloma. Citing interim data from its CARTITUDE-4 trial, the pharma giant said patientsContinue Reading

Novo Nordisk to spend $4.1B to build new plant for obesity drugs in N.C.

In: Finance

Victor Golmer/iStock Editorial via Getty Images Novo Nordisk (NVO) will invest $4.1B to build a second fill and finish manufacturing facility in Clayton, N.C. focused on injectables medications, including current and future ones for obesity. The development comes as Novo, which makes the weight loss drug Wegovy (semaglutide), and rivalContinue Reading

GLP-1 drugs linked to reduced dementia risk: study (NYSE:NVO)

In: Finance

Devonyu A new peer-reviewed study suggested this week that GLP-1 drugs, popularly used for weight loss, are associated with a lower risk of dementia in older people with diabetes. The trial considered real-world data from Sweden using more than 88,000 patients aged 65 or older with type 2 diabetes mellitusContinue Reading

drugs

Oppenheimer’s best SMID-cap ideas: AI, health, obesity drugs, and more (NYSEARCA:IWO)

Mizuho starts Neumora at outperform, bullish on lead drug’s prospects (NASDAQ:NMRA)

Study links GLP-1 drugs, metformin to lower risk of certain cancers (NYSE:NVO)

J&J Carvykti beat standard drugs in blood cancer (NYSE:JNJ)

Novo Nordisk to spend $4.1B to build new plant for obesity drugs in N.C.

GLP-1 drugs linked to reduced dementia risk: study (NYSE:NVO)

How Rocket Companies modernized their data science solution on AWS | Amazon Web Services

AWS and DXC collaborate to deliver customizable, near real-time voice-to-voice translation capabilities for Amazon Connect | Amazon Web Services